



TDF

TROPICAL DISEASE FOUNDATION, INC.

ANNUAL REPORT

2022-2023

MESSAGE FROM CEO

Dear Friends,

Stepping up during critical times is as important as being steadfast in our commitment to our organizational priorities.

Three years ago, by leveraging on the inherent strength of our organization, we embarked on scaling up our operations with new programs and approaches that use innovative tools, products, and technologies to deliver high-impact key results to our beneficiaries.

As a major part of our strategy for expansion and growth, we created more partnerships with other nonprofits and social change organizations which enabled other intermediaries and groups to offer high-impact and integrated projects and programs through research, service delivery, training, and sharing best practices.

Though we cannot be confident of what the future holds, we can always be clear and resolved in our mission, the eradication of infectious diseases of public health importance as one of the keys for national prosperity. We embody the trademark of optimism we shared with our Founder, Dr. Thelma E. Tupasi, and in her belief that a better and healthier world is possible through our shared vision, values, and actions.

We are like the trees in a forest that tell their story via rings. The first ring is a beginning with subsequent rings celebrating growth. The spaces between the rings explain how this growth happened. By leveraging on the talents and resources of the public, private and philanthropic sectors, we did what no one of us could achieve alone.

"By uniting the passion and commitment of our donors, partners, advisors, community leaders, and stakeholders, we created sustainable solutions that will continue to affect lives for years to come."

This year's Annual Report highlights how we worked towards long-term solutions to the problems of TB and HIV in the country, while continuing to provide relief to the current needs of the patients accessing the services we offer. As we work, we grow, we learn, we adapt and we innovate. Our partners made our tree ring grow wider and deeper.

Thank you for your many compassionate actions, support, partnership, and friendship over the years. I remain grateful, humbled, and inspired.

JULIUS A. LECCIONES, MD, PhD, DPA
President and CEO



ABOUT TDF

The Tropical Disease Foundation, Inc. (TDF) is a non-profit organization established in 1984 by a group of physicians from the Research Institute for Tropical Medicine.

Led by its founding chairman and former Secretary of Health, Dr. Jesus Azurin, TDF committed to excellence in research, service, and training.

Since its inception, TDF has been at the forefront of pioneering initiatives in fighting tropical diseases, leaving an indelible mark on the landscape of public health.

OUR VISION

Equitable universal access to health for national prosperity.

OUR MISSION

National and local community development through research, training, service, and healthcare delivery in the prevention and control of infectious diseases of public health importance.

OUR THRUSTS

- 01.**
To conduct research, training and service in infectious diseases of public health importance
- 02.**
To enter into partnership with public and private agencies in the implementation of programs in the control of infectious diseases
- 03.**
To ensure technology transfer in developing human resources for health nationally and internationally through collaboration with national and international institutions
- 04.**
To serve as a national and international training center for infectious diseases



TABLE OF CONTENTS

02	Researches
25	Services
31	Trainings
36	Community Engagement
40	Partnerships
43	Accomplishments
54	Financial Summary



TDF Annual Report 2022-2023

RESEARCHES



Tropical Disease Foundation, Inc.



Completed
Month 12 Visit
103/160

Completed target recruitment
(160 participants): 17 Oct 2022

This study evaluates IGRA positivity in high TB burden populations and aims to determine the proportion of IGRA positivity at different sites.

It seeks to develop capacity for conducting a Phase 3 TB vaccine efficacy study. However, it is not intended to generalize findings on the prevalence of latent TB.

1

Gates MRI TBV02-E01 Study

Period of Coverage:

01 Aug 2022 – 31 Jul 2023

Area of Coverage:

Makati, Manila and Pasay Cities

Target Reach: Makati, Manila and Pasay Cities

Site initiation: 25 Jul 2022

Site Recruitment Activation: 17 Aug 2022

2

Global TB Alliance Paternity Survey (Extension)

Period of Coverage:

01 Aug 2022 – 18 Nov 2022

Area of Coverage:

Makati City

Target Reach: Makati City

Protocol Title: A Survey Assessing Male Reproduction During or After Treatment Containing Pretomanid

Sponsor: Global TB Alliance

Initiation Project Duration

(covering experimental arm participants):
07 Jun 2021 – 16 Feb 2022

This survey gathers data on male participants who took part in a TB Alliance clinical trial (STAND, Nix-TB, SimpliciTB, or ZeNix) and received treatment containing pretomanid.

Participants were asked about partner births during or after their pretomanid treatment.

A follow-up study, launched in October 2022, focused on participants in the control arm (standard TB regimen) and concluded on November 18, 2022, with interviews conducted for all eligible participants.



3

Project Title:
Long COVID

Research Title: A Retrospective and Prospective, Observational, Multicenter, Cohort Study to follow-up Hospitalized Patients with Confirmed COVID-19 infection in the Philippines

Sponsor: Philippine Center for Health Research and Development (PCHRD)

Period of Coverage: 16 Jun 2023 - 15 Jun 2023

Area of Coverage: Luzon, Visayas and Mindanao

Target Reach: 10 sites

Through the Philippine Society of Microbiology and Infectious Diseases (PSMID), TDF submitted an application for additional funding to the Philippine Center for Health Research and Development (PCHRD) 2023 Call for Proposals (CFP) to sustain the ISARIC CCP Project, focusing on the Long COVID or COVID-19 Follow-up study.

Following selection from a shortlist, the proposal was presented to PCHRD Enbanc on May 23, 2023, and approved on June 19, 2023.

Funding was allocated and made available under the accounts of PSMID as the Implementing Agency and TDF as the Cooperating Agency.

4

Wellcome Foundation Projects

Period of Coverage:
01 Aug 2022 - 31 Jul 2023

Area of Coverage:
4th District of Metro Manila

Target Reach: Makati City

The University of Oxford has been granted funding by the Foreign, Commonwealth & Development Office / Wellcome Epidemic Preparedness to implement the **International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) Clinical Characterisation Protocol (CCP)** in Low- and Middle-Income Countries.

In Southeast Asia, TDF was chosen to be the **Regional Research Coordinator** to roll-out the project.



5

Project Title:
WELLCOME Project (Qualitative Research Training)

Research Title: “A Qualitative Study on the Implementation and Adoption of evidence-based Philippine COVID-19 Living Recommendations by Physicians in Three Local Regions in the Country”

Period of Coverage: 08 Dec 2022 - 02 May 2023

Area of Coverage: Luzon, Western Visayas and Northern Mindanao

Target Reach: Physicians

Three research fellows representing Luzon, Visayas, and Mindanao were selected by TDF under the WELLCOME Project to participate in a Qualitative Research Training Workshop, along with three additional attendees from TDF.

Following the 10th session, the team produced a Qualitative Research Abstract, which was presented in Rio de Janeiro, Brazil, during the ISARIC Members Assembly Meeting on May 18, 2023.

Currently, the team is preparing a manuscript for publication based on the research paper.





A Qualitative Study on the Implementation and Adoption of Evidence-based Philippine COVID-19 Living Recommendations by Physicians in Three Local Regions in the Country

JC Caoili^{1,4}, AG Jumeras², MR Macatangay¹, KS Taladua³, GI Balane⁴, ES Joson⁴

¹Makati Medical Center, ²West Visayas State University Medical Center, ³Capitol University Medical Center, ⁴Tropical Disease Foundation



BACKGROUND

Infectious diseases contributes to significant morbidity and mortality in the Philippines. Development of Clinical Practice Guidelines (CPGs) has been recognized as an important strategy to standardize the management of patients with infections including COVID-19.

The Department of Health spearheaded the development of the Philippine COVID-19 Living Recommendations and Unified Algorithm to provide evidence-based guidelines in the management of patients with COVID-19.

This qualitative study was undertaken to determine how the Philippine COVID-19 guidelines were utilized by the physicians in the three major regions in the country.

METHODS

Semi-structured interview

- Total of 18 face-to-face and virtual interviews (via zoom) with 6 respondents each from the National Capital Region, Western Visayas and Northern Mindanao
- 16 interviews recorded then transcribed and two transcribed in real-time
- All transcriptions were translated into English for analysis

Population

- Physicians who are general practitioners, specialists or experts from different subspecialties practicing in private or government hospitals in any of the three regions of the Philippines
- All participant physicians managed COVID-19 patients from March 2020 to March 2022

Content Analysis


- Similarities, differences and peculiarities were identified from the responses
- Major themes were identified per region and overall

RESEARCH QUESTION

How are the Philippine COVID-19 clinical practice guidelines implemented and adopted by the clinical practitioners per region and in the country?

RESULTS

Patient Management accounts for the majority of the reasons where CPGs are Beneficial in Clinical Practice for physicians in the Philippines



Resources accounts for the majority of the factors that Limit Physicians in Adopting COVID-19 Guidelines



Majority of physicians in the Philippines use Local CPGs



Considerations in using COVID-19 CPG during health emergencies



FINDINGS:

CPG Benefits : Most physician respondents said that CPGs are beneficial for Patient Management.

CPG Utilization : Majority use local guidelines as compared to international CPGs. Most are willing to utilize CPGs every time it is available and updated. During COVID-19 surges, physicians from the NCR access and implement CPGs earlier in comparison to physicians in the two other regions. This reflects the usual COVID-19 surge scenario where the NCR usually experiences the initial surge in cases before other regions in the country. Respondents from the regions outside the NCR, said that during COVID-19 surges, they learn COVID-19 management strategies from physicians practicing in the NCR through webinars and online conferences.

CPG Adherence: Availability of Resources and PhilHealth insurance provisions were major considerations.

Consideration in using CPG during health emergencies: Lack of resources is the main limiting factor in implementing COVID-19 guidelines. The most important factor is applicability of CPGs in the local setting.

CONCLUSION and RECOMMENDATIONS

- Clinicians value CPGs for patient management. CPGs are readily available, and physicians are open to adopt this in their practice.
- Lack of resources, both diagnostic and treatment are the major limiting factors in adopting the COVID-19 guidelines.
- Important factors considered by physicians in using CPGs is its applicability to the local setting as well as PhilHealth provision.
- CPGs should be continuously developed for emerging infections. CPGs should provide recommendations for best practice in patient management, consider resources that are available locally for applicability. PhilHealth should adopt updated CPGs to improve physician's adherence to the CPGs. CPGs should be accessible and disseminated in multiple venues including best-practice sharing webinars and conferences.

ACKNOWLEDGEMENT This work was supported by the Foreign, Commonwealth & Development Office and Wellcome [222048/Z/20/Z] through the Tropical Disease Foundation, Inc. Special thanks to all respondents and to the Global Outbreak Alert and Response Network (GOARN), International Severe and Acute Respiratory Infection Consortium (ISARC) and to Dr. Jeni Stollow, Tulane University

The purpose of the study is to:

[1] standardize data collection for independent (local) and pooled (global) analysis

[2] characterize COVID-19 during the acute phase and evaluate the long-term health implications in recovered individuals, identifying risk factors, immune responses, and biomarkers for severe illness.



6

Inactivated COVID-19 Vaccine (Vero Cells)

A study to evaluate efficacy, safety and immunogenicity of SARS- CoV-2 Vaccine (Vero Cells), inactivated in healthy adults aged 18 years and older

Sponsor: Shenzhen Kangtai Biological Products Co., Ltd. Beijing Minhai Biological Technology Co., Ltd.

Principal Investigator: Dr. Gelza Mae A. Zabat

Site: Tropical Disease Foundation, Inc - Makati



Inactivated COVID-19 Vaccine (Vero Cells) **Accomplishments**

1251

Total enrolled patients

18

months

Trial duration

Ethics Committee Initial Approval: 29 Jun 2021

Site Initiation Visit: 03 Aug 2021

Start of enrollment: 14 Aug 2021

End of enrollment: 15 Oct 2021



7

DeINS1-2019-nCoV-RBD-OPT1)

A Global, Multi-center, Randomized, Double-blind, Placebo controlled Phase III Clinical Trial to Evaluate the Protective Efficacy and Safety of Influenza Virus Vector COVID-19 Vaccine for Intranasal Spray (DeINS1-2019-nCoV-RBD-OPT1) in Adults Aged 18 Years and Older

Sponsor: Shenzhen Kangtai Biological Products Co., Ltd. Beijing Minhai Biological Technology Co., Ltd.

Principal Investigator: Dr. Gelza Mae A. Zabat

Site: Tropical Disease Foundation, Inc - Makati



DeINS1-2019-nCoV-RBD-OPT1) **Accomplishments**

1594

Total enrolled patients

18 months

Trial duration

Ethics Committee Initial Approval: 24 Sept 2021

Site Initiation Visit: 14 Dec 2021

Start of enrollment: 18 Dec 2021

End of enrollment: 11 Feb 2022



8

ARCoV-005

A Global, Multi-center, Randomized, Double-Blind, Placebo-controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine in Population Aged 18 Years and Older (ARCoV-005)

Sponsor: Yuxi Walvax Biotechnology Co., Ltd., Walvax Biotechnology Co.,Ltd. & Suzhou Abogen Biosciences Co., Ltd.

Principal Investigator: Dr. Rod Castro

Site: Tropical Disease Foundation, Inc.
Bautista, Pangasinan Local Government Unit



ARCoV-005 Accomplishments

821

Total enrolled patients

Trial duration

30 Nov 2021 to
6 Sept 2023

Ethics Committee Initial Approval: 03 Aug 2021

Site Initiation Visit: 30 Nov 2021

Start of enrollment: 5 Dec 2021

End of enrollment: 16 Feb 2022



9

LG-VCCL002 Clinical Trial

Protocol Title: A Multicenter, Open-Label, Interventional Phase 3b Study to Evaluate the Safety, One-Year Antibody Persistence, and Priming Immune Responses of Three Doses of Eupolio Inj. (Inactivated Polio Vaccine [Sabin Strains]) and the Immunogenicity of Two Doses of Eupolio Inj. Following Three Doses of bOPV in Infant

Sponsor: LG Chem, Ltd

Principal Investigator: Dr. Maria Rosario Z. Capeding

Site: Medical Research Unit, Medical Plaza, Makati City

Period of Coverage: March 2023 to May 2024

Area of Coverage: Makati City

Target Reach: 42-56 days infants



Medical Research Unit Clinical Trial Team

LG-VCCL002 Clinical Trial Accomplishments

155

Total enrolled patients

Ethics Committee Initial Approval: 13 February 2023

Site Initiation Visit: 01 March 2023

Start of enrollment: 10 March 2023

End of enrollment: 05 April 2023

Study Status: Follow-up phase



10

64281802DNG2004 Clinical Trial

Protocol Title: A Phase II, Randomized, Double-blind, Placebo-controlled, Double-dummy, Multicenter Trial Assessing the Efficacy and Safety of Two Dose Regimens of JNJ-64281802 for the Prevention of Dengue Infection

Sponsor: Janssen Research & Development, LLC

Principal Investigator: Dr. Maria Rosario Z. Capeding

Site: San Jose Clinical Trial Site, San Pablo City, Laguna

Period of Coverage: April 2023 to April 2025

Area of Coverage: San Pablo City, Laguna

Target Reach: 18 years to 65 years



San Jose Clinical Trial Team

64281802DNG2004 Clinical Trial Accomplishments

17

Total enrolled patients

Ethics Committee Initial Approval: 05 July 2022

Site Initiation Visit: 18 April 2023

Start of enrollment: 01 June 2023

End of enrollment: ongoing

Study Status: ongoing recruitment



11

Protocol Title: International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) Clinical Characterisation Protocol (CCP)

Protocol Name: ISARIC CCP

Sponsor: Foreign, Commonwealth & Development Office/Wellcome Epidemic Preparedness

Start Date: June 1, 2021

End Date (Initial Grant): November 30, 2022

Project Extension: December 1, 2022 – May 31, 2023

Period of Coverage: Primary Grant (18months) 01 June 2021 – 30 Nov 2022

Project Extension (6months) 01Dec 2022 – 31 May 2023

No-Cost Extension (7months) 01 June 2023 – 31 Dec 2023

Area of Coverage: Southeast Asia

Target Reach: 6 sites

The Philippines CCP database was established with Makati Medical Center (MMC) serving as the pilot site.

Applications are pending for Baguio General Hospital, Davao Doctors Hospital, and two hospitals in Bacolod.

Philippine General Hospital is interested in joining the collaboration, seeking to electronically extract data from their existing database to RedCap.

MMC, as the pilot site, has IRB approval to initiate the Long COVID Study and can conduct telephonic interviews with post-hospitalized COVID-19 patients at any time.

2,950

COVID-19 patients encoded
out of 5,113 COVID-19 admitted to
MMC from 2020 to present



1

VAC31518COV3009 Clinical Trial

Protocol Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adults Aged 18 Years and Older

Sponsor: Janssen Vaccines & Prevention B.V.

Principal Investigator: Dr. Maria Rosario Z. Capeding

Site: San Francisco Multipurpose Bldg., San Pablo City, Laguna

Period of Coverage: January 2021 to June 2023

Area of Coverage: San Pablo City, Laguna

Target Reach: 18 years and older



San Pablo City Clinical Trial Team

VAC31518COV3009 Clinical Trial Accomplishments

308

Total enrolled patients

Ethics Committee Initial Approval: 28 December 2020

Site Initiation Visit: 25 January 2021

Start of enrollment: 06 February 2021

End of enrollment: 30 March 2021

Study Status: Completed



2

GBP510_003 Clinical Trial

Protocol Title: A Phase III, Randomized, Active-controlled, Observer-blind, Parallel-group, Multi-center Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine adjuvanted with AS03 (GBP510) in Adults Aged 18 Years and Older

Sponsor: SK Bioscience Co. Ltd./ IVI

Principal Investigator: Dr. Maria Rosario Z. Capeding

Site: San Francisco Multipurpose Bldg., San Pablo City, Laguna

Period of Coverage: December 2021 to February 2023

Area of Coverage: San Pablo City, Laguna

Target Reach: 18 years and older



San Pablo City Clinical Trial Team (IVI)

GBP510_003 Clinical Trial Accomplishments

682

Total enrolled patients

Ethics Committee Initial Approval: 05 October 2021

Site Initiation Visit: 02 December 2021

Start of enrollment: 06 December 2021

End of enrollment: 29 December 2021

Study Status: Completed



3

JSVCT109 Clinical Trial

Protocol Title: A Global Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cells) for the Prevention of COVID-19 in Adults Aged 18 Years and Older

Sponsor: WesVac Biopharma Co., Ltd.

Principal Investigator: Dr. Maria Rosario Z. Capeding

Site: Alaminos Clinical Trial Site, Alaminos, Laguna

Period of Coverage: July 2021 to January 2023

Area of Coverage: Alaminos, Laguna

Target Reach: 18 years and older



Alaminos, Laguna Clinical Trial Team

JSVCT109 Clinical Trial **Accomplishments**

3,054

Total enrolled patients

Ethics Committee Initial Approval: 29 June 2021

Site Initiation Visit: 12 July 2021

Start of enrollment: 22 July 2021

End of enrollment: 08 December 2021

Study Status: Completed



4

YS-302 Clinical Trial

Protocol Title: A Phase II/III, Randomized, Double-blinded Study to Evaluate the Efficacy, Safety and Immunogenicity of a Booster Dose of PIKA Recombinant Protein COVID-19 Vaccine (CHO cell, S protein) in Adults \geq 18 Years Old Who Received 2 or more doses of Inactivated Covid-19 Vaccine

Sponsor: Yisheng Biopharma (Singapore) Pte. Ltd.

Principal Investigator: Dr. Maria Rosario Z. Capeding

Site: CRU Presnedi Bldg. Muntinlupa City

Period of Coverage: September 2022 to January 2024

Area of Coverage: Muntinlupa City

Target Reach: 18 years and older



Muntinlupa City Clinical Trial Team

YS-302 Clinical Trial **Accomplishments**

1,502

Total enrolled patients

Ethics Committee Initial Approval: 22 August 2022

Site Initiation Visit: 19 September 2022

Start of enrollment: 27 October 2022

End of enrollment: 20 December 2022

Study Status: Follow-up phase



Clinical Trials under Dr. Charissa Fay Corazon C. Borja- Tabora as Principal Investigator

1

Protocol Title:

A Phase III, Randomized, Double-Blind, Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Developed by Sinovac Biotech Co., Ltd. Compared to a Licensed Quadrivalent Influenza Vaccine, VaxigripTetra™, in Individuals Aged 3 Years and Older

Initial submission submitted: November 18, 2022

EC Approval: February 5, 2023

Accomplishments

350

Target

451

Enrolled





2

Protocol Title:
A Phase I-II, Double-Blind, Randomized, Placebo-Controlled Study of a T Cell Priming Next-Generation Vaccine Against Coronavirus Disease in Healthy Adults

SJREB Approval: March 14, 2023

EC Approval: May 9, 2023

Subject Target/ Enrolled: Not yet initiated



3

Protocol Title:
A Phase III, Randomized, Comparator-Controlled, Double-Blind, Multicenter Study to Evaluate the Immunogenicity, Safety, and the Consistency of Three Consecutive Lots of a PIKA Rabies Vaccine (Vero Cell) for Human Use, Freeze-Dried in Healthy Adult Subjects Using a Post-Exposure Prophylaxis Schedule

EC Approval: April 14, 2023

Accomplishments

500

Target

562

Enrolled



4

Protocol Title:

A Phase III, Randomized, Observer-Blinded Study to Evaluate the Efficacy, Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age or Older

EC Approval: May 2023

Accomplishments

400

Target

400

Enrolled



Clinical Trial under Dr. Edison Alberto as Principal Investigator

1

CLO-SCB-2019-003 Study

Protocol Title:

A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/ Alum-Adjuvanted Recombinant SARS- CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) for the Prevention of SARS-CoV-2-mediated COVID-19 in Participants Aged 12 Years and Older

Sponsor: Clover Biopharmaceuticals AUS Pty Ltd

Site: Health Index Multispecialty Clinic Barangay Mambog 1, Bacoor, Cavite 4102 Philippines

Site Initiation Visit: January 12, 2021

Study Duration: 13 months

CLO-SCB-2019-003 is a double-blind, randomized, controlled, multi-country study of CpG 1018/Alumadjuvanted recombinant SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) to assess the efficacy, immunogenicity, reactogenicity, and safety compared with control (placebo).

The study included adult subjects aged 18 years and older, and adolescents 12 to less than 18 years of age, enrolled at selected sites.

Adult



Screened



Screen Failed



Enrolled

Screening: March 24, 2021
Enrollment Started (First Subject): March 24, 2021
Enrollment Finished (Last Subject): June 29, 2021

Adolescent



Screened



Screen Failed



Enrolled

Screening: January 05, 2022
Enrollment Started (First Subject): January 05, 2022
Enrollment Finished (Last Subject): March 14, 2022



2

HH-Trans-001 Study

Protocol Title:

Impact of Vaccination using the Clover SCB-2019 COVID-19 vaccine on Household Transmission of SARS-CoV-2 Infection

Sponsor: International Vaccine Institute (IVI)

Site: Health Index Multispecialty Clinic Barangay Mambog 1, Bacoor, Cavite
4102 Philippines

Site Initiation Visit: June 30, 2021

Study Duration: 8 weeks after the second dose of SCB-2019; the actual duration will depend on the duration of the main trial

Description: Observational Study

This study measures the total incidence rate of SARS-CoV-2 infection among household members not participating in the Clover SCB-2019 trial, adjusted for intraclass correlation within households.

Accomplishments



Screened



Screen Failed



Enrolled

Screening: July 14, 2021

Enrollment Started

(First Subject): July 14, 2021

Enrollment Finished

(Last Subject): March 14, 2022

Last Subject Visit

(End of Study Visit): February 3, 2022



3

2021L001 Study

Protocol Title:

A Multi-National, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated for the Prevention of COVID-19 in Healthy Adults Aged 18 Years and Older

Sponsor: Shenzhen Kangtai Biological Products Co., Ltd. Beijing Minhai Biotechnology Co., Ltd.

Site: Health Index Multispecialty Clinic Barangay Mambog 1, Bacoor, Cavite 4102 Philippines

Date of Initiation Visit: June 30, 2021

Date of Screening Started: August 16, 2021

Date Enrollment Started (First Subject): August 19, 2021

Date Enrollment Finished (Last Subject): October 30, 2021

Primary study objective:

To evaluate the efficacy of candidate vaccine in the prevention of symptomatic COVID-19 cases 14 days after full vaccination, in healthy adults aged 18 years and older.

Study Duration:

Participants will be followed for at least 12 months after full vaccination. Based on primary endpoint and anticipated enrollment period per country of 2~6 months, the study is anticipated to last for 15~19 months.

Accomplishments

2,560

Screened

484

Screen Failed

2,076

Enrolled



4

GBP510_003 Study

Protocol Title:

A Phase III, Randomized, Active-controlled, Observer-blind, Parallel-group, Multi-center Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine adjuvanted with AS03 (GBP510) in Adults Aged 18 Years and Older.

Sponsor: SK Bioscience Co., Ltd. International Vaccine Institute (IVI)

Site: Health Index Multispecialty Clinic Barangay Mambog 1, Bacoor, Cavite 4102 Philippines

Site Initiation Visit: December 01, 2021

Date of Screening Started: December 06, 2021

Date Enrollment Started (First Subject): December 14, 2021

Date Enrollment Finished (Last Subject): January 07, 2022

Approximately 1,950 adults with no history of SARS-CoV-2 infection or COVID-19 vaccination, confirmed by a SARS-CoV-2 rapid antibody kit at screening, were enrolled in Cohort 1 (Immunogenicity Cohort). Another 2,040 adults were enrolled in Cohort 2 (Safety Cohort) regardless of their serostatus confirmed by the same screening method.

Approximately 20% of the participants were aged 65 years and older. Participants were expected to participate for up to 13 months, with a 12-month follow-up after the second vaccination.

Accomplishments

Cohort 1 (Immunogenicity): 140
Cohort 2 (Safety): 718

Cohort 1 (Immunogenicity): 10
Cohort 2 (Safety): 174

Cohort 1 (Immunogenicity): 130
Cohort 2 (Safety): 544



Screened



Screen Failed



Enrolled



5

KD414-03 Study

Protocol Title:

A Phase 3, Randomized, Double-Blind, Active-Controlled, Confirmatory Study to Compare the Immunogenicity, Efficacy, and Safety of KD-414 Vaccine and Vaxzevria Vaccine in Adults Aged 18 to 40 Years Old

Site: Health Index Multispecialty Clinic Barangay Mambog 1, Bacoor, Cavite 4102 Philippines

Initiation Visit: June 07, 2022

Date of Screening Started: July 01, 2022

Date Enrollment Started (First Subject): July 01, 2022

Date Enrollment Finished (Last Subject): July 22, 2022

The KD-414 vaccine is being developed to prevent COVID-19. This study primarily evaluates its immunogenicity, along with its efficacy and safety. A Phase 1/2 trial is ongoing, with no safety concerns reported for a third dose given after 6 months.

Accomplishments

333

Screened

142

Screen Failed

191

Enrolled





TDF Annual Report 2022-2023

SERVICES



Tropical Disease Foundation, Inc.



1

DOTS Clinic and Satellite Treatment Center for DRTB

Supporting Organization(s):

DOTS Clinic TB kits (medicines) and lab supplies are provided by the Department of Health through the Makati City Health Department.

Period of Coverage: 01 Aug 2022 - 31 Jul 2023

Area of Coverage: Metro Manila

Target Reach: Makati City



TDF offers a public-private mixed DOTS clinic for patients who have symptoms suggestive of TB or who are suspected to have tuberculosis by healthcare providers.

TDF TB-DOTS Clinic caters to patients who live or work within the catchment area whether they are walk-in or are referred by physicians from nearby hospitals such as Makati Medical Center, diagnostic clinics, schools, business establishments and offices.

TDF-DOTS Clinic aims to support the achievement of Millennium Development Goals by expanding services to more clients in the future.

Since the onset of the pandemic, the clinic has adopted community-based treatment and leveraged technology for remote patient monitoring.

DOTS Clinic and Satellite Treatment Center for DRTB **Accomplishments**

228

Presumptive TB Cases Screened

18% increase from 2022

6,372

Patients Enrolled

14% increase from 2022

24

cured

Treatment Completed: 21
Ongoing Treatment: 3



2

Satellite Treatment Center for MDR-TB

Period of Coverage:

01 Aug 2022 - 31 Jul 2023

Area of Coverage:

4th District of Metro Manila

Target Reach: Makati City



The STC currently has 1 PBSP-hired nurse on board. Patients are followed-up regularly through phone calls and/or internet messaging platforms in between monthly clinic visits.

Satellite Treatment Center for MDR-TB **Accomplishments**

174

Presumptive DR-TB Screened and Tested

19

Confirmed Rifampicin Resistant TB

35

Cases Registered

19

Bacteriologically-confirmed RR/MDR-TB

3

Clinically-diagnosed MDR-TB

13

Other Drug-resistant TB case



3

TDF-Radisen X-ray Facility

Launch Date: 27 Sept 2021

Period of Coverage: 01 Aug 2022 – 31 Jul 2023

Area of Coverage: Makati City

Target Reach: Makati City

Radisen, a developer of artificial intelligence (AI) technology for digital radiography, provided TDF with AI units for mobile x-ray vans, allowing efficient on-site sputum screening.

Radisen sponsors equipment maintenance, ensuring our AI-assisted X-ray machine functions optimally. We prioritize image quality, staff training, patient education, and regulatory compliance, positioning TDF as a reliable TB healthcare provider.



Clients accommodated for Fiscal Year

YEAR	TOTAL CENSUS
2021 (NOV 1 - DEC 15)	14
2022 (JAN 7 - DEC 15)	155
2023 (JAN 26 - DEC 15)	209
TOTAL PATIENTS	378

The TDF X-ray Clinic seeks to engage in TB research trials and strengthen relationships with ongoing projects like Epic, Gates MRI, TDF DOTS, PMDTs, and TDF OPD.

Our primary focus is on streamlining patient flow, minimizing waiting time through the effective TB screening one-stop-shop system.



EpiC Project

Meeting Targets and Maintaining Epidemic Control (EpiC) is a global project funded by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and the U.S. Agency for International Development (USAID).

Its goal is to achieve and maintain HIV epidemic control. Led by FHI 360, the project spans five years, from April 15, 2019, to April 14, 2024.

As a Sub-Grantee of the EpiC Grant in the Philippines, TDF will provide services to support the National HIV Program.

In FY23, TDF focused on expanding viral load testing and treatment monitoring in key sites like The Primary by TDF, SAIL, and SHIP Clinics.

TDF obtained a **Limited Services Capability License**, ensuring rapid delivery of viral load results.



Site visit by DOH-MMCHD (Mr. Dominic Sotto, Ms. Christine Jay Agatep, Mr. John Axl Torres, and Ms. Zarah Dayco) to TDFI on May 10, 2022, to assess the HIV Testing Facility Set-up

Obejctives

- To help control epidemics among men who have sex with men (MSM) and transgender people (TG) in the National Capital Region.
- To enhance the effectiveness of antiretrovirals for treatment and prevention through early detection of acute HIV infection (AHI) and improved access to viral load testing.

Activities

- Scale up Rapid HIV Diagnostic Algorithm (rHIVda) and access to POC Viral Load Testing for Eligible PLHIV
- Implement Same Day or Rapid ART Initiation
- Pilot pooled HIV testing for early diagnosis of acute HIV infection (AHI), along with cost-benefit analysis and identifying obstacles for confirmatory testing in rapid HIV diagnostic algorithm (rHIVDA)



HIV Counseling and Testing Training by CAMP Pag-ayo Inc. at Jade Hotel and Suites, Makati, April 26-29, 2022



EpiC Project

Awareness campaigns such as '**PrEPFound**' and '**UFirst**' were launched to advocate Pre-Exposure Prophylaxis and Viral Suppression. Partnerships with the Makati City Health Office were established to enhance service delivery.

Navigating the complex Department of Health (DOH) regulations remains a challenge for TDF's laboratory in fully implementing the Rapid HIV Diagnostic Algorithm (RHIVDA). Additionally, TDF's research on Acute HIV Infection (AHI) diagnosis shifted protocols from Dried Blood Spot specimens to Cobas Plasma Separation Cards (PSC). However, discussions are needed in FY24 to align with USAID recommendations regarding Cobas PSC's off-label use.

Despite this, TDF EpiC-Project remains committed to the research and will resume once a clear path forward is established.



HIV Counseling and Testing Training by CAMP Pag-ayo Inc. at Jade Hotel and Suites, Makati, April 26-29, 2022



FHI 360 EPIC Subgrant General assembly held at Madison 101 Hotel Quezon City, June 15-17, 2022

Site visit by USAID (Dr. Deidra Parrish, Mr. Mikael Navarro), FHI360 (Ms. Clarence Faye Salvador, Mr. Jeremiah Serrano), and DOH-MMCHD (Dr. Julius Lecciones and TDFI EpiC Project Team) to TDFI on June 7, 2022, for assessing HIV Testing Facility Set-up and rHIVDA laboratory accreditation.



TDF Annual Report 2022-2023

TRAININGS



Tropical Disease Foundation, Inc.



EXTRAMURAL

Makati Medical Center Fellowship Rotation Program

Period of Coverage:

01 Aug 2022 - 31 Jul 2023

Cooperating Agency:

Makati Medical Center

Target Reach: Makati Medical Center Infectious Diseases and Pulmonology Fellows

A training program has been established in collaboration with the MMC Infectious Diseases and Pulmonology Departments to familiarize and expose their fellows to TB clinical management and laboratory TB assessments.

Typically, rotations last between 1 to 2 months.

The program commenced in September 2014, and TDF is currently hosting **15** fellows for the year.

TITLE OF SEMINAR/TRAINING

"TB in Special Situations" Training for Health Workers Providing TB Services

INCLUSIVE DATE

August 23, 2022

FACILITATED BY

Dr. Rholine Gem Martin Veto



INTRAMURAL

EMPLOYEE NAME	TITLE OF TRAINING	DATE
Anthony Geronimo	First International Conference on Biosafety & Biosecurity	August 10-12, 2022
Mark Aaron Dela Torre Ma. Joanna Eunice Calaogan Catherine Anne Dente Glenn Balane	HIV Counseling to Testing Training	August 24-26, 2022
Rogeselle Monton	Advancing sustainable advancing of key population led Health Services in Asia	August 29-31, 2022
Harley Ronniekson Khom Emmanuel Reyes Ma. Joanna Eunice Calaogan Trizia Maye Suriaga Camille Ocampo Catherine Anne Dente Angelito Catindig Evelyn Joson Marita Nucum Glaiza Erika Hernandez Christine Larryse Evangelista Rhandy Rowan John Phillip Ubalde	Technical Writing Workshop	September 13-16, 2022
Anthony Geronimo Maita Benavente	Write it Right	November 16 & 23, 2022



INTRAMURAL

EMPLOYEE NAME	TITLE OF TRAINING	DATE
Rogeselle Monton Mark Aaron Dela Torre	Community Based HIV Screening and DBS Collection Training (Region 3 Batch)	November 21-26, 2022
Anthony Geronimo Rogeselle Monton Rhandy Rowan	Write it Right	December 1, 2022
Manny Directo Raffy Castillo Ricardo Taylo Jr. Abegail Fondales Rupert Rey Flores Ma. Joanna Eunice Calaogan Marilou Salvana Ma. Lourdes Cabanatan Harley Ronniekson Kihom Welmar Cruel Rogeselle Monton Abegail Daluz Ma. Begonia Baliwagan Christian Salido	Basic Life Support	December 5-6, 2022
Dr. Rholine Gem Martin Veto	Integrated DOTS Phase II: Training of Mentors	January 31 – February 3, 2023
John Phillip Ubalde Glenn Balane	The V.A.L.U.E. of the Mid-Level Management: How to Empower Middle Management to Drive Organizational Success	February 8, 2023



INTRAMURAL

EMPLOYEE NAME	TITLE OF TRAINING	DATE
Mark Aaron Dela Torre Welmar Cruel Jaypee Albert Mendoza Ma. Begonia Baliwagan	HIV Primary Care Training	February 8-10, 2023
Angelito Catindig Maria Lourdes Cabanatan	Mastering Value Added Tax	March 17, 2023
Angelito Catindig Maria Lourdes Cabanatan	Mastering Withholding Taxes	March 17, 2023
Ma. Begonia Baliwagan	ART Literacy and Orientation	April 17, 2023
Kim Oliver Puyot Rogeselle Monton Jaypee Albert Mendoza Renato Roque Mark Aaron Dela Torre	Client-Centered Case Management Training	May 21-26, 2023
Evelyn S. Josen Glenn I. Balane	Qualitative Research Training	May 31, 2023
Marita Nucum	SSS In-Depth Seminar	July 31-August 1, 2023



TDF Annual Report 2022-2023

COMMUNITY ENGAGEMENT



Tropical Disease Foundation, Inc.



World TB Day Mini-grant (TB Alliance)

Period of Coverage:

March - April 2023

Area of Coverage:

Makati City

Target Reach: Employees of Private company in Construction and Mining Industry



In collaboration with the PCHI Occupational Health Team, this initiative aimed to raise awareness among employees, including office staff and site workers exposed to dust and smoke.

During the seminar, attendees gained valuable insights about tuberculosis (TB), learning about its causes, transmission, prevention, and management.

Misconceptions about TB were addressed, and workplace applications such as relevant laws, policies, dust control, exposure management, and the use of personal protective equipment (PPE) were discussed.

The presentation also included updates on recent advancements in TB care, including new diagnostic techniques and treatment options.

The activity concluded with an agreement between the company's Occupational Health Team and our clinic for the referral and management of employees suspected of having TB.

Detailed referral procedures were discussed to ensure a smooth continuation of care for company employees.



WORLD AIDS DAY 2022

THEME: EQUALIZE



In December 2022, the Tropical Disease Foundation, Inc. (TDF) marked World AIDS Day with the theme "EQUALIZE."

By embracing the theme, TDF highlighted the importance of providing equitable healthcare regardless of factors like gender, age, or socioeconomic status.

Through its advocacy for health equity, TDF aims to break down barriers to healthcare access and contribute to ending the global HIV crisis.



During the observation of World AIDS Day Celebration attended by FHI360



EpiC Grant Program Manager Mr. Joshua C. Young



International AIDS Candlelight Memorial 2023: Light It Makati

A collaborative effort between the Tropical Disease Foundation, Inc., the Local Government of Makati City, and the University of Makati. Held under the theme "**Spread Love and Solidarity, not Stigma and Fear,**" its goal was to combat HIV/AIDS-related discrimination and fear.

Generous support from sponsors like PEPFAR and USAID facilitated TDF's active participation, advocating against stigma. The memorial honored those lost to AIDS while celebrating champions in HIV advocacy.

The event's impact extended to **400** university students and neighboring communities, emphasizing the importance of raising awareness among younger generations regarding HIV/AIDS-related issues and combating stigma.





TDF Annual Report 2022-2023

PARTNERSHIPS



Tropical Disease Foundation, Inc.



Our partnerships foster innovation and knowledge exchange, promoting best practices and capacity-building.

We advocate alongside diverse partners, including governmental bodies, NGOs, healthcare providers, researchers, and international agencies.

Together, we drive synergies to enhance healthcare services and strengthen the national HIV response.

Recognizing the complexity of healthcare challenges, we prioritize collaboration across organizations to catalyze advancements in service delivery, treatment accessibility, and HIV prevention through resource pooling and expertise sharing.



Class Photo of the Provider-Initiated HIV Counseling to Testing Training for CBOs and Healthcare Workers 2023, c/o TDFI. – September 4-6, 2023



Class Photo of the Syndromic STI and OI Management Training for Healthcare Workers 2023, c/o TDFI. - September 7-9, 2023



TDFI attended the Annual Regional Strategic Information and Response Planning Workshop (STIR-UP) held at The Bayleaf Hotel Cavite last September 19-22, 2023



Clinic Case Manager – Mr. Renato Roque attended the Learning Session conducted by FHI-EpiC - held at B Hotel last September 22, 2023



Provider Initiated Counseling to Testing orientation for the HIV Program Staff of Ospital ng Makati (OsMak) conducted by the Makati Social Hygiene Clinic and supported by TDFI – September 29, 2023

Through shared strategies, we elevate healthcare quality and inclusivity, particularly in HIV response efforts.



TDF Annual Report 2022-2023

ACCOMPLISHMENTS



Tropical Disease Foundation, Inc.



Leveraging Innovations for Faster Treatment of TB (LIFT-TB)

98%

Treatment success rate (Bedaquiline-Pretomanid-Linezolid – BPaL Operational Research)

88

Stakeholders participated in the Research Implementation Review (RIR) and Scale-up Workshop to aid the transition to programmatic implementation of BPaL-based regimens, February 8-10, 2023

270

Local and international partners joined the Hybrid Symposium on 'Current Strategies Against Drug-Resistant TB' held during World TB Day, March 24, 2023

Training of National TB Reference Laboratory (NTRL) and Philippine Tuberculosis Society Inc (PTSI) staff on MGIT-DST by laboratory experts from the International TB Research Center (ITRC), South Korea in Sep 2022 →



← Monitoring in Region 3 and NCR conducted covering 2 OR sites and 4 health centers (iDOTS facilities) in May – June 2023

4

Abstracts accepted for presentation to the 2023 Union World Conference on Lung Health in Paris, France

13

Articles published on the TDF website highlighting project updates and milestones



TB Innovation and Health Strengthening System (TBIHSS)



TDF Granted Sub-award from FHI 360 for TBIHSS

The Tropical Disease Foundation, Inc. (TDF) was approved as a sub-award recipient of Family Health International (FHI) 360 under the TB Innovations and Health System Strengthening (TBIHSS) project with Prime Award Number 72049218CA00001.

This USAID project is designed to bring dynamic and strategic approach to accelerate the fight against TB in the Philippines. It will run for four months, with two and a half months allocated to field operations.

The ACF activities in urban poor communities will be conducted in the two (2) cities in Metro Manila:

CALOOCAN CITY

1. Bagong Silang
2. Bagumbong
3. Camarin

QUEZON CITY

1. Gulod
2. Pasong Tamo
3. Payatas

The primary objective of the activity is to provide primary healthcare services including TB screening coupled with promotion of healthy habits in urban poor communities in Caloocan City and Quezon City, Metro Manila.



The Primary Clinic



TDF is Now a Certified HIV Primary Care Facility

The Primary Clinic by TDF achieved a significant milestone on March 20, 2023, by obtaining its Certificate of Accreditation as a Primary HIV Care Facility, offering comprehensive services including antiretroviral therapy (ART) and essential laboratory support.

This accreditation shows The Primary Clinic's dedication to delivering exceptional healthcare for individuals living with HIV. It highlights adherence to stringent standards to ensure comprehensive care, treatment, and support services.

This accomplishment solidifies TDF's reputation as a trusted healthcare institution committed to meeting the needs of those with HIV.






Our distinguished Board of Trustees during the Launching of The Primary Clinic by TDF together with the FHI360 and USAID Philippines as Sponsor and Development Partners






TDFI HIV PRIMARY CARE FACILITY

KPI REPORTING

December 2022 to September 2023








HIV PREVENTION CAMPAIGN OUTPUT


PrEP Found

APR - SEPT 2023



ART TREATMENT

APR - SEPT 2023





TDF Laboratory Report

In FY 2022–2023, TDF's Laboratory Department achieved significant milestones in tuberculosis, HIV, and COVID-19 research and diagnostics. As a leading organization dedicated to infectious disease prevention, TDF continually advanced knowledge boundaries.

In November 2022, TDF joined the A5356 trial as the Mycobacteriology Laboratory, collaborating with De La Salle Health Science Institute. This Phase II study evaluates Linezolid Dosing Strategies for drug-resistant tuberculosis treatment.

TDF expanded TB operations and established an HIV Testing Laboratory, initiating viral load testing using the GeneXpert system and rapid diagnostic screening.

In the COVID-19 fight, TDF conducted RT-PCR tests and participated in vaccine trials.

Throughout the fiscal year, the Laboratory engaged in **11** projects for TB, HIV, and COVID-19 diagnosis and treatment, maintaining its international recognition for research and trials.

PROJECTS/ACTIVITIES OF THE LABORATORY



Gates MRI-TBD06-201

A Phase 2b/c trial will assess the efficacy and safety of 2–4 months' treatment with regimens containing Bedaquiline, OPC-167832, and Sutezolid, plus either Pretomanid or Delamanid, in adults with pulmonary tuberculosis.

Agreements were signed in the fiscal year, and patient enrollment is slated for December 2023.

In preparation, Microbiology Consultant Gabriel Rojas-Ponce visited the laboratory from July 24–28.



NC-009

A pan-Phase 2 Clinical Trial incorporating elements of Phase 2a, b, and c trials will assess the safety and efficacy of a combination of TBAJ-876, pretomanid, and linezolid to expedite and enhance treatment for drug-sensitive and drug-resistant TB.

The study will span 21 clinical trial sites across Georgia, the Philippines, South Africa, Tanzania, and Uganda, with TDF Laboratory serving as the country's Mycobacteriology Laboratory. Robert Hunt visited the laboratory in January 2023, and enrollment of the first patient is anticipated in December 2023.



LIST OF PROJECTS/STUDIES/ACTIVITIES OF THE LABORATORY DEPARTMENT FOR FY 2022-2023

#	Project ID	Disease Focus	Project Description	Sponsor/Partner	Role	# of samples processed
1	PHOENIX A5300B	TB	Phase III, open label, multi-center trial with a cluster-randomized superiority design (eligible contacts in the same household are a cluster), to compare the efficacy and safety of 26 weeks of delamanid versus 26 weeks of isoniazid for preventing confirmed or probable active TB during 96 weeks of follow-up among high-risk household contacts of multidrug-resistant tuberculosis (MDR) TB patients.	AIDS Clinical Trials Group	Contracted by De La Salle Health Science Institute as Mycobacteriology Laboratory	417
2	A5356	TB	Phase II, Prospective, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety/Tolerability of Two Linezolid Dosing Strategies in Combination with a Short Course Regimen for the Treatment of Drug-Resistant Tuberculosis	AIDS Clinical Trials Group	Contracted by De La Salle Health Science Institute as Mycobacteriology Laboratory	227
3	DRAMATIC-TB Trial	TB	Prospective, Randomized, Partially Blinded, Phase 2 Study of the Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB	Boston University	Contracted by De La Salle Health Science Institute as Mycobacteriology Laboratory	516
4	CoACH-TB	TB		Department of Science and Technology	Contracted by De La Salle Health Science Institute as Mycobacteriology Laboratory	104
5	TMC207-C211	TB	Phase 2, Open-label, Multicenter, Single-arm Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Anti-mycobacterial Activity of TMC207 in Combination With a Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for the Treatment of Children and Adolescents 0 Months to <18 Years of Age Who Have Confirmed or Probable Pulmonary MDR-TB	Janssen	Country Mycobacteriology Laboratory	114
6	PMDT	TB		Philippine Business for Social Progress	Rapid TB Diagnostic and TB Culture Laboratory	5567
7	2021L001	COVID-19	A multi-national, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy, safety and immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), inactivated for the prevention of COVID-19 in healthy adults aged 18 years and older	Sherchen Kangai Biological Products Co. Ltd.	Confirmatory Laboratory for RT-PCR	16
8	JSVCT109	COVID-19	A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells), for the prevention of COVID-19 in adults aged 18 years and older	WestVac BioPharma Co., Ltd.	Confirmatory Laboratory for RT-PCR	20
9	Bloomberry	COVID-19		Bloomberry Resorts and Hotels, Inc.	RT-PCR Laboratory for the detection of SARS-CoV-2	83821
10	Viral Load Testing	HIV		EpiC Project	Viral Load Testing Laboratory	587
11	HIV Screening	HIV		EpiC Project	HIV Screening Facility	28

Table 1. List of Projects/Studies/Activities of the Laboratory Department for FY 2022-2023.

EXTERNAL QUALITY ASSURANCE PERFORMANCE

Assay:	Interferon-Gamma Release Assay	
Provider:	UK NEQAS	
Panel	Date	Result/Score
224	26-Aug-22	100%
225	21-Oct-22	0%
226	01-Dec-22	100%
231	14-Mar-23	100%
232	20-Apr-23	100%
233	22-Jun-23	100%

Table 2. Performance summary for IGRA EQA.

Assay:	GenoType MTBDRsl LPA	
Provider:	SmartSpot	
Panel	Date	Result/Score
2022-2	22-Sep-22	100%
2022-3	21-Nov-22	67%
2023-1	26-Jul-23	100%

Table 4. Performance summary for GenoType MTBDRsl LPA.

Assay:	GenoType MTBDRplus LPA	
Provider:	SmartSpot	
Panel	Date	Result/Score
2022-2	22-Sep-22	100%
2022-3	21-Nov-22	100%
2023-1	26-Jul-23	100%

Table 3. Performance summary for GenoType MTBDRplus LPA.

Assay:	GeneXpert MTB/RIF Ultra	
Provider:	SmartSpot	
Panel	Date	Result/Score
2022-2	25-Aug-22	100%
2022-3	12-Nov-22	100%
2023-1	10-May-23	100%




Table 5. Performance summary for GeneXpert MTB/RIF Ultra.




Provider:	Integrated Quality Laboratory Service	
Survey Number:	14	
Area	Average Scoring (Max 4)	Average in %
Microscopy	4.00	100.00%
Identification	4.00	100.00%
First Line DST	4.00	100.00%
Second Line DST	4.00	100.00%
Average	4.00	100.00%

Table 6. Performance summary for IQLS EQA Panel.



TDFI LABORATORY VL TESTING APR - SEPT 2023







TDF Annual Report 2022-2023

FINANCIAL SUMMARY



Tropical Disease Foundation, Inc.



INDEPENDENT AUDITORS' REPORT

The Board of Trustees
Tropical Disease Foundation, Inc.
Philippine Institute of Tuberculosis Building
Amorsolo Street corner Urban Avenue
Barangay Pio Del Pilar, Makati City

Report on the Financial Statements

Opinion

We have audited the accompanying financial statements of Tropical Disease Foundation, Inc. (the Foundation), a non-stock, non-profit organization, which comprise the statements of assets, liabilities and fund balances as at July 31, 2023 and 2022, and the statements of revenues and expenses, statements of changes in fund balances and statements of cash flows for the years then ended, including a summary of significant accounting policies.

In our opinion, the financial statements present fairly, in all material respects, the financial position of the Foundation as at July 31, 2023 and 2022, and its financial performance and its cash flows for the years then ended in accordance with Philippine Financial Reporting Standard for Small and Medium-sized Entities (PFRS for SME).

Basis for Opinion

We conducted our audits in accordance with Philippine Standards on Auditing (PSA). Our responsibilities under those standards are further described in the *Auditors' Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Foundation in accordance with the Code of Ethics for Professional Accountants in the Philippines (Code of Ethics) together with the ethical requirements that are relevant to the audit of the financial statements in the Philippines, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with PFRS for SME, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Foundation's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Foundation or to cease operations, or has no realistic alternative but to do so.




Those charged with governance are responsible for overseeing the Foundation's financial reporting process.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with PSA will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, these could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with PSA, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the Foundation's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Foundation's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Foundation to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in manner that achieves fair presentation.





REYES TACANDONG & Co.
FIRM PRINCIPLES. WISE SOLUTIONS.

- 3 -

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audits.

Report on the Supplementary Information Required under Revenue Regulations No. 15-2010 of the Bureau of Internal Revenue

Our audits were conducted for the purpose of forming an opinion on the basic financial statements taken as a whole. The supplementary information on taxes and licenses in Note 20 to the financial statements is presented for purposes of filing with the Bureau of Internal Revenue and is not a required part of the basic financial statements. Such information is the responsibility of the management of Tropical Disease Foundation, Inc. The information has been subjected to the auditing procedures applied in our audits of the basic financial statements and in our opinion, the information is fairly stated in all material respects in relation to the basic financial statements taken as a whole.

REYES TACANDONG & Co.


DAPHNE A. JAMOTILLO

Partner

CPA Certificate No. 100039

Tax Identification No. 206-551-995-000

BOA Accreditation No. 4782; Valid until April 13, 2024

SEC Accreditation No. 100039-SEC Group A

Issued August 3, 2021

Valid for Financial Periods 2021 to 2025

BIR Accreditation No. 08-005144-018-2021


Valid until July 1, 2024

PTR No. 9564576

Issued January 3, 2023, Makati City

November 6, 2023

Makati City, Metro Manila





TROPICAL DISEASE FOUNDATION, INC.
(A Non-stock, Non-profit Organization)

STATEMENTS OF ASSETS, LIABILITIES AND FUND BALANCES

		July 31	
	Note	2023	2022
ASSETS			
Current Assets			
Cash and cash equivalents	4	P98,945,706	P64,581,113
Receivables	5	16,166,782	13,086,539
Investments in trust funds	6	74,140,254	72,979,865
Other current assets		1,188,137	428,536
Total Current Assets		190,440,879	151,076,053
Noncurrent Assets			
Investment property	7	2,084,677	3,085,742
Property and equipment	8	56,875,752	63,211,974
Net retirement plan asset	17	252,600	-
Other noncurrent assets	9	1,654,653	505,174
Total Noncurrent Assets		60,867,682	66,802,890
		P251,308,561	P217,878,943
LIABILITIES AND FUND BALANCES			
Current Liabilities			
Payables	10	P18,216,544	P12,779,530
Income tax payable		2,016,436	-
Total Current Liabilities		20,232,980	12,779,530
Noncurrent Liabilities			
Net retirement benefit liability	17	-	4,334,004
Deferred tax liability	18	-	52,147
Total Noncurrent Liabilities		-	4,386,151
Total Liabilities		20,232,980	17,165,681
Fund Balances			
General fund		172,077,082	134,380,572
Restricted fund	12	32,373,000	32,373,000
Capital fund		26,587,429	33,924,716
Other comprehensive income		38,070	34,974
Total Fund Balances		231,075,581	200,713,262
		P251,308,561	P217,878,943

See accompanying Notes to Financial Statements.



TROPICAL DISEASE FOUNDATION, INC.
(A Non-stock, Non-profit Organization)

STATEMENTS OF REVENUES AND EXPENSES

	Note	Years Ended July 31	
		2023	2022
SOURCES OF FUNDS	13	₱139,698,257	₱144,180,489
PROGRAM EXPENSES	14	(90,660,920)	(92,290,629)
GENERAL AND ADMINISTRATIVE EXPENSES	15	(19,846,985)	(20,900,398)
OTHER INCOME	16	3,879,678	6,900,568
EXCESS OF REVENUES OVER EXPENSES BEFORE INCOME TAX		33,070,030	37,890,030
PROVISION FOR (BENEFIT FROM) INCOME TAX	18		
Current		2,762,954	2,663,266
Deferred		(52,147)	52,147
		2,710,807	2,715,413
EXCESS OF REVENUES OVER EXPENSES		30,359,223	35,174,617
OTHER COMPREHENSIVE INCOME (LOSS)			
<i>Item to be reclassified to profit or loss when realized</i>			
Unrealized gain (loss) on fair value changes of investments	9	3,096	(9,864)
TOTAL COMPREHENSIVE INCOME		₱30,362,319	₱35,164,753

See accompanying Notes to Financial Statements.



TROPICAL DISEASE FOUNDATION, INC.
(A Non-stock, Non-profit Organization)

STATEMENTS OF CHANGES IN FUND BALANCES

		Years Ended July 31	
	Note	2023	2022
GENERAL FUND BALANCE			
Balance at beginning of year		₱134,380,572	₱97,822,521
Excess of revenues over expenses		30,359,223	35,174,617
Transfer from capital fund	8	8,945,745	8,608,773
Transfer to capital fund	8	(1,608,458)	(7,225,339)
Balance at the end of year		172,077,082	134,380,572
RESTRICTED FUND BALANCE			
	12	32,373,000	32,373,000
CAPITAL FUND BALANCE			
Balance at beginning of year		33,924,716	35,308,150
Transfer to general fund	8	(8,945,745)	(8,608,773)
Additions to property and equipment	8	1,608,458	7,225,339
Balance at the end of year		26,587,429	33,924,716
OTHER COMPREHENSIVE INCOME			
<i>Reserve for fair value changes of investments</i>			
Balance at beginning of year		34,974	44,838
Unrealized gain (loss) on fair value changes	9	3,096	(9,864)
Balance at the end of year		38,070	34,974
		₱231,075,581	₱200,713,262

See accompanying Notes to Financial Statements.



TROPICAL DISEASE FOUNDATION, INC.
(A Non-stock, Non-profit Organization)

STATEMENTS OF CASH FLOWS

	Notes	Years Ended July 31	
		2023	2022
CASH FLOWS FROM OPERATING ACTIVITIES			
Excess of revenues over expenses before income tax		P33,070,030	P37,890,030
Adjustments for:			
Depreciation and amortization	8	8,945,745	8,608,773
Retirement benefit expense (income)	17	(2,586,604)	1,659,518
Investment income	6	(1,026,220)	(3,776,585)
Loss on write-off of receivables	5	266,830	844,572
Interest income	4	(42,091)	(29,585)
Donated laboratory equipment	8	-	(2,983,470)
Excess of revenues over expenses before working capital changes		38,627,690	42,213,253
Increase in:			
Receivables		(3,347,073)	(1,789,692)
Other current assets		(759,601)	(61,161)
Increase in payables		5,437,014	5,464,142
Net cash generated from operations		39,958,030	45,826,542
Contributions paid	17	(2,000,000)	-
Income tax paid		(746,518)	(2,972,561)
Interest received		42,091	29,585
Benefits paid	17	-	(5,550,596)
Net cash provided by operating activities		37,253,603	37,332,970
CASH FLOWS FROM INVESTING ACTIVITIES			
Proceeds from withdrawals of investments in trust funds	6	-	35,324,977
Additions to:			
Investments in trust funds	6	(134,169)	(35,561,369)
Property and equipment	8	(1,608,458)	(4,241,869)
Decrease (increase) in other noncurrent assets		(1,146,383)	214,518
Net cash used in investing activities		(2,889,010)	(4,263,743)
NET INCREASE IN CASH AND CASH EQUIVALENTS		34,364,593	33,069,227
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR		64,581,113	31,511,886
CASH AND CASH EQUIVALENTS AT END OF YEAR	4	P98,945,706	P64,581,113

See accompanying Notes to Financial Statements.

MEET OUR TEAM

BOARD OF TRUSTEES

CHAIRMAN OF THE BOARD

Dr. Ruben L. Encarnacion

MEMBERS

Dr. Claver P. Ramos

Dr. Roberta C. Romero

Dr. Camilo C. Roa Jr.

Dr. Socorro P. Lupisan

Dr. Raymundo W. Lo

Dr. Ma. Imelda Josefa Quelapio

Mrs. Mercedes A. Solon

Atty. Edwin R. Abella

EXECUTIVE OFFICERS

PRESIDENT AND CEO

Julius A. Lecciones, MD, PhD, DPA

VP FOR PROGRAM SUPPORT

Leilani C. Naval

MANAGEMENT OFFICERS

LABORATORY MANAGER

Anthony A. Geronimo

CLINIC PHYSICIAN

Dr. Rholine Gem Martin S. Veto

FINANCE MANAGER

Rhandy R. Rowan

HR MANAGER

Marita I. Nucum

IT MANAGER

Evelyn S. Joson

PROGRAM MANAGER, EPIC

Rogeselle B. Monton

Connect with us:

 +632 8894 074143

 www.tdf.org.ph

 inquiries@tdf.org.ph

